Basiliximab, previously identified as CHI 621 and possessing the molecular identifier 179045-86-4, represents a monoclonal agent utilized primarily in avoiding acute repudiation following organ transplantation . This engineered antibody specifically interacts with the interleukin-2 (IL-2) receptor , effectively inhibiting IL-2 communication and sub